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Abstract
The human papillomavirus (HPV) is the most widespread sexually transmitted infection in
America. College-aged students are a high-risk group for HPV transmission, but their HPV
vaccination rates are low. The purpose of this evidence-based project was to implement an HPV
vaccination program at a health science center university student health clinic to increase
vaccination rates to meet the guidelines of the American College Health Association (ACHA)
and the Centers for Disease Control and Prevention (CDC). The objectives of this project were as
follows: 1) to educate providers and staff on the importance of the HPV vaccine; 2) to increase
HPV vaccine recommendations to students by providers and staff; 3) to increase the HPV
vaccination rate among students offered the vaccine; and 4) to increase the vaccination rate
among all eligible students. Prior to implementation, 100% of staff were educated on the HPV
vaccination guideline, resulting in a 33% improvement in test scores between pre- and post-tests.
Of 205 student visits, 10.7% were recommended the vaccine. Sixty-four percent of students who
were offered the vaccine accepted the immunization. The overall clinic vaccination rate postimplementation was 4.5%. Limitations of the project included staffing issues, problems with
staff completing the education in a timely manner, providers’ perceptions of time constraints,
students not remembering their HPV vaccine status, and a lack of knowledge around insurance
coverage for the vaccine. The vaccination of even one previously unimmunized student can slow
the spread of HPV; therefore, this project affected practice and patient outcomes through
implementation of an HPV vaccination program, increasing HPV vaccination rates in an at-risk
population.
Keywords: human papillomavirus vaccine, human papillomavirus
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Implementation of the Human Papillomavirus Vaccine Among Health Professions Students
The Human Papillomavirus (HPV) is the most widespread sexually transmitted infection
in America (Centers for Disease Control and Prevention [CDC], 2017). It affects 79 million
Americans every year in the form of oropharyngeal and cervical cancers as well as genital warts.
HPV can also cause vulvar, vaginal, penile, or anal cancers (CDC, 2017). It is transmitted via
oral, vaginal, or anal sex with another person who is harboring the virus. In many cases, infected
men and women exhibit no symptoms.
The Food and Drug Administration has approved an HPV vaccine as a means of
preventing HPV-related conditions. The public tends to have a limited understanding of the
importance of the vaccine. Some believe the HPV vaccine is only for young women from 11 to
26 years old; however, young men within this age range can receive the vaccine as well. Some
parents feel the vaccine is not necessary for their children and contend that it may encourage
sexual activity; nevertheless, vaccination in childhood is intended to prevent HPV-related
cancers and genital warts later in life. Some individuals believe the HPV vaccine may be harmful
despite having been Food and Drug Administration approved. Thus, vaccine-related education,
provider encouragement, and staff collaboration are needed to increase the rate of HPV
vaccination among eligible individuals.
Statement of the Problem
HPV is the most common sexually transmitted infection. Approximately 80 million
people have HPV, and 14 million are estimated to become infected with the virus each year
(CDC, 2016). HPV has over 150 strains, six of which can contribute to oropharyngeal, anal,
cervical, vaginal, vulvar, and penile cancers in men and women (CDC, 2016; Osazuwa-Peters et
al., 2017). About 70% of sexually active individuals are infected with HPV, which has been
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prominently linked with cervical cancer (Dominiak-Felden et al., 2013). The two HPV genotypes
responsible for 73% of cervical cancers are strains 16 and 18 (CDC, 2016). The incidence of
cervical cancer has increased in women under 50 years old. Over 300,000 women pass away
from cervical cancer each year, approximately 4,000 of whom live in the United States (CDC,
2016). In addition to cervical cancer, HPV strains 6 and 11 lead to genital warts. The remaining
five strains—31, 33, 45, 52, and 58—cause an additional 15% of cervical cancers (CDC, 2016).
The current recommendation is to vaccinate boys and girls ages 11 to 12 (Cohen & Legg,
2014). A Healthy People 2020 goal is to increase cervical cancer prevention, measured as 80%
of eligible candidates receiving the HPV vaccination at an early age (Osazuwa-Peters et al.,
2017; Ratanasiripong, Cheng, & Enriquez, 2013). However, if an individual has not received the
HPV vaccine by college age, then the three-dose series should be encouraged. University clinics
provide an ideal venue for administration.
Some individuals may consider university students too old to receive the vaccine,
assuming it is too late for them to be vaccinated; accordingly, HPV vaccination rates are much
lower in this population. The American College Health Association has stated that approximately
35% of men and 55% of women in college stated they had received at least one dose of the HPV
vaccine (as cited in Vázquez-Otero et al., 2016). This finding supports low HPV vaccination
rates among the college-aged population although most individuals within this age range are
sexually active. For example, in one study, nearly 78% of students surveyed reported having
engaged in sexual intercourse (Marchand, Glenn, & Bastani, 2012). College students are
therefore at high risk of transmitting and contracting HPV (Cohen & Legg, 2014).
Government officials have not prioritized the HPV vaccine for social and political
reasons. Rumors abound that the HPV vaccine will increase sexual activity and lead teens and
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young adults to have more sexual partners. Many religious and social groups have therefore
spurned this vaccine. Many state higher education institutions also do not have policies
mandating HPV vaccination; thus, more education and awareness is needed to increase public
acceptance and understanding of the importance of the HPV vaccine.
There are many reasons for low HPV vaccination completion rates among college
students (Rashid, Labani, & Das, 2016). For example, many university students may not have
had a chance to receive the vaccine as pediatric patients. If they were offered the vaccine, their
parents may have refused the vaccination or were not provided sufficient information to make an
informed decision regarding vaccination. Due to the fast pace and lack of time in clinics,
healthcare providers face various obstacles to thoroughly educating patients about the HPV
vaccine. At the university level, students can make their own medical decisions without parental
consent (Barnard, George, Perryman, & Wolff, 2017). Therefore, better awareness and education
regarding the HPV vaccine is imperative to increasing immunization rates among eligible
university students (Cohen & Legg, 2014; Marchand, Glenn, & Bastani, 2012).
Background and Significance
Approximately 14 million young adults are infected with HPV annually, and nearly half
the population will come into contact with HPV at some point in their lives (CDC, 2016;
McCave, Chertok, Winter, & Haile, 2013). Each year, 19,200 women and 11,600 men are
diagnosed with an HPV-related cancer in the United States HPV-associated oropharyngeal
cancers are most common in men, with 9,100 men diagnosed in America every year (CDC,
2017). Cervical cancer is the third most common cancer caused by HPV; 12,000 women in the
United States are diagnosed with it annually. Of all HPV-related diseases, cervical cancer is the
most serious female condition. It is most common in women, especially those who are sexually
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active (Ndikom & Ofi, 2012). Oropharyngeal cancer is the sixth most common HPV-related
disease, causing 70% of cases in women and men. Prevention of these and other HPV-related
conditions through administration of the HPV vaccine can potentially protect thousands of men
and women (including those already infected with HPV) from serious and possibly fatal cancers.
The major HPV vaccine available to prevent cervical cancer in the United States is the 9valent/9vHPV or Gardasil 9 vaccine (CDC, 2017). Merck manufactures Gardasil 9 (and
previously the quadrivalent, Gardasil 4); GlaxoSmithKline produced Cervarix, a bivalent
vaccine, until 2016. Gardasil 4 debuted in June 2006 and was initially available for young
women before being approved for use in young men in October 2009; it covered HPV strains 6,
11, 16, and 18. In 2006, the National Advisory Committee on Immunization Practices in the
United States recommended the vaccine for girls ages 11 to 12. The bivalent vaccine, Cervarix,
was released in October 2009 for young women and covered HPV strains 16 and 18 (DominiakFelden et al., 2013).
These vaccines have since been replaced by Gardasil 9, which covers both sexes from 9
to 26 years of age and protects against strains 6, 11, 16, 18, 31, 33, 45, 52, and 58. Men between
22 and 26 years old are only recommended to receive the vaccination if they are
immunocompromised or have homosexual partners (CDC, 2017). Gardasil 9 can prevent up to
80% of cervical cancers worldwide (CDC, 2017), and in trials for vaccine approval, it was nearly
100% effective in preventing cervical, vulvar, and vaginal diseases caused by the five additional
HPV types (31, 33, 45, 52, and 58) (Chatterjee, 2014). Since the end of 2016, most clinics have
begun using Gardasil 9 to vaccinate eligible individuals who consent to receive the vaccine.
Contraindications for the HPV vaccine include the potential for Cervarix to cause anaphylaxis in
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individuals allergic to latex, whereas the Gardasil types carry the risk of an increased reaction in
individuals allergic to yeast.
HPV vaccination rates are low for many reasons, including speculation that the vaccine
promotes sexual activity; thus, many parents of college students do not advocate for the vaccine
prior to their children leaving home (Ratanasiripong et al., 2013). Additionally, there is a low
completion rate of the three-dose series among those who have received the HPV vaccine, with
minorities having a lower completion rate than other groups. African-American women have the
highest death rate from cervical cancer (Galbraith et al., 2016). African-Americans are also the
least educated about the HPV vaccine compared to non-Hispanic whites, who are more willing to
receive the vaccine when offered (Osazuwa-Peters et al., 2017). Many minority parents
mistakenly believe that their child will contract HPV from the vaccine. Another discrepancy is
prevalent among college-aged women, 70% of whom report being sexually active while less than
50% have completed the three-dose HPV vaccination course at 0, 1–2, and 6 months
(Ratanasiripong et al., 2013).
A lack of understanding and awareness of the devastation associated with cervical cancer
has led to many problems (Marchand, Glenn, & Bastani, 2012). The first HPV vaccine was
released over 10 years ago, yet many college students have not been vaccinated. Factors such as
cost, insufficient access to care, and poor public awareness partially explain why individuals do
not take advantage of this preventative option to protect against cervical cancer. Other
individuals are nervous about receiving the vaccine due to a lack of knowledge about its benefits
(Remes, Smith, Alvarado-Llano, Colley, & Levesque, 2014). The HPV vaccine requires a threedose series and thus necessitates patient effort to ensure completion. If the series is initiated prior
to age 15, only two doses are necessary, rendering earlier vaccination more efficacious. Another
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issue involves informing the patient that the HPV vaccine is due, especially for the three-dose
series. Notification methods, such as electronic reminders through a patient portal, have been
shown to increase course completion among patients in the primary care setting (Wright et al.,
2011).
Increasing the rate of HPV vaccination depends on patients’ perceptions of the vaccine
and associated marketing strategies. Choosing not to vaccinate will reduce the protection the
HPV vaccine provides the population (Osazuwa-Peters et al., 2017; Simms et al., 2016). Thus,
cervical cancer may result in higher rates of morbidity and mortality. Also, the lack of a mandate
for the vaccine contributes to low HPV vaccination rates. The government can assist in
increasing vaccination by requiring individuals between 9 and 26 years old who do not want the
vaccine to opt out in lieu opting in for the vaccine. Opting out occurs when an individual must
specifically state he or she does not want a vaccine.
Additional efforts must be devoted to marketing the HPV vaccine to promote and
increase HPV vaccination rates. The incidence of HPV-related oropharyngeal and anal cancers in
men is rising, but men are less aware of the HPV vaccine than women (Osazuwa-Peters et al.,
2017). Not all providers routinely recommend the HPV vaccine, and many parents have stated
that if a provider does not recommend that their son or daughter receive the vaccine, then they
are less likely to have their child vaccinated (McRee, Gilkey, & Dempsey, 2014). Providers may
not recommend the vaccine for several reasons: time constraints; difficulty advocating for sexual
health, especially to parents of young children; absence of data regarding long-term side effects
of the vaccine; and the fact that HPV vaccination is not mandatory. Providers also tend to
recommend the vaccine to women more than men (McRee et al., 2014). Lastly, even when
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providers recommend the vaccine, some parents will use avoidance strategies to circumvent their
child’s vaccination (e.g., stating they wish to delay the HPV vaccine to a subsequent visit).
Assessment
The location for this evidence-based project was a south-central Texas health science
center university student health clinic. The university clinic provides primary care services (e.g.,
annual physicals, immunizations, and blood work), care for acute illnesses and minor injuries,
and health promotion services to approximately 3,000 students. All students are required to carry
either university-offered health insurance or another form of health coverage. Five nurse
practitioner providers work varying hours in the clinic along with a registered nurse (RN),
licensed vocational nurses (LVNs), and two medical assistants (MAs). The clinic is nursemanaged by a physician who serves as the delegating physician per Texas law. The clinical
manager reported that the clinic engages in about 8,000 encounters annually. Eighty-four percent
of patients seen in the clinic are students in their twenties, and most are women. The
predominant ethnicities are Caucasian and Hispanic. Many patients who come to the clinic have
their own transportation. The most common reasons for visitation are immunizations and
allergies.
Although many visits are related to immunizations, a microsystem assessment conducted
in Spring 2016 demonstrated that the HPV vaccine was not routinely recommended to students
because the clinic did not stock the vaccine. If a student wanted the vaccine, then he or she
would be instructed to go to a local pharmacy or another primary care provider who offered it.
For many students, the student health clinic serves as their primary care provider while attending
school; therefore, the student has two providers. Many students within the eligible age range for
the HPV vaccine were also being missed because they were assumed to have received the
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vaccine while living at home. Moreover, providers did not regularly address the need for the
HPV vaccine during appointments, especially annual physicals. During an observed clinic day,
two women were encouraged to receive the HPV vaccine because they were younger than age
26; however, men seen during the same time frame were never offered the vaccine.
The microsystem assessment also revealed that the clinic’s electronic medical records
system had no way to alert the provider that a student was eligible for the HPV vaccine; there
was also no manual way to notify the provider of the need for the vaccine. Because the vaccine
was not being regularly offered, no mechanism was in place to assist students in remembering to
come for the remaining doses in the HPV series. Furthermore, even though the university is a
healthcare-focused education institution, no pamphlets or information on the HPV vaccine were
available either in the clinic or on the university website to increase student awareness. The
availability of such materials would allow students to become educated about the vaccine and
make an informed decision on whether to receive it. Lastly, at the university level, no electronic
hold on a student’s account prevented him or her from registering, as is customary for other
immunizations, because the HPV vaccine is not mandatory.
One benchmark for the HPV vaccine in college-aged students is the American College
Health Association (ACHA) guidelines. The ACHA guidelines refer to the CDC as a resource
for more information, offering recommendations for immunizations within the college setting.
Regarding the HPV vaccine, all women between 11 and 26 years old should be vaccinated with
the bivalent, quadrivalent, or 9-valent vaccine. Men between 11 and 21 years old should receive
the quadrivalent or 9-valent vaccine, as should men who have sex with other men or those who
are immunocompromised and between 11 and 26 years of age (ACHA, 2017).

IMPLEMENTATION OF THE HUMAN PAPILLOMAVIRUS VACCINE

16

The HPV vaccine should be available as a three-dose series (administered at 0, 1–2, and 6
months) in the college setting for young adults who have not been vaccinated. The clinic should
prioritize implementation of an HPV vaccination program because thousands of potentially
eligible students may be at risk for cervical and oropharyngeal cancers as well as genital warts if
they are not vaccinated against HPV. Texas has not mandated the HPV vaccine as it has for other
immunizations, thereby lowering immunization rates. On February 2, 2007, then-governor Rick
Perry signed an executive order that would have mandated that all girls entering the 6th grade
receive the HPV vaccine; however, the Texas governor reversed his stance shortly thereafter
amid criticism from conservative Texans.
Organization Readiness for Change and Stakeholder Engagement
Upon review of the ACHA guidelines and the results of a Spring 2016 microsystem
assessment, it was determined that the stakeholders in the organization were ready for change.
Numerous talks with the clinical manager and the Dean of the School of Nursing indicated that
both advocated for offering the HPV vaccine at the student health clinic. All parties agreed that
providing the vaccine would be imperative to primary care provided at the university student
health clinic. By offering the HPV vaccine, students could obtain the three necessary doses. The
clinical manager supported stocking the clinic with the HPV vaccine and implementing a
marketing campaign to spread awareness about it. All providers and staff expressed their support
of the plan to begin to vaccinate individuals who consented to receive the HPV vaccine. Policymaking was also part of the plan and was conducted in collaboration with a panel of individuals
integral to the launching of the HPV vaccination program in the student health clinic.
In summary, there was an identified deficit in the student health clinic regarding the
prevention of HPV-related illnesses due to the on-site unavailability of the HPV vaccine.
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Documentation presented another problem: students who had received the HPV vaccine were not
labeled as such through their student records, and those who had not received the vaccine were
not identified and could number in the thousands. Many students younger than 26 years who
were eligible to receive the vaccine could not receive it in the student clinic. Although students
could visit a local pharmacy to receive the vaccine along with corresponding documentation in
their school vaccination record, this process was inconvenient and seldom offered. Health
insurance (whether school-provided or private) covers preventative vaccines, including the HPV
vaccine. Thus, the cost of the vaccine was not a barrier to program implementation because the
clinic would bill most insurance companies.
Project Identification
Purpose
The purpose of this evidence-based project was to implement an HPV vaccination
program at a health science center university student health clinic to increase vaccination rates to
meet the guidelines of ACHA and the CDC. The project represents a primary care initiative to
prevent future HPV-related diseases such as cervical and oropharyngeal cancers.
Objectives
The objectives of this project were as follows:
1. One hundred percent of providers and staff would be educated on the importance of the
HPV vaccine and the new HPV vaccination program in the clinic.
2. Provider recommendations for the HPV vaccine to eligible students would increase from
0% initially to 50% post-implementation.
3. The number of eligible students offered the HPV vaccine who received a dose would
increase from 0% initially to 50% post-intervention.
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4. The HPV vaccination rate among eligible students who visited the student health clinic
would increase from 0% initially to 60% post-intervention.
Anticipated Outcomes
The anticipated short-term outcome for this project was an increased HPV vaccination
rate among students attending the university, increased awareness and education around the HPV
vaccine among students at the university, and an increase in recommendations by providers, with
staff collaboration, for the HPV vaccine to eligible students. In addition, upon completion of the
implementation period, the clinic would align with Healthy People 2020 goals and the ACHA
and CDC guidelines. The anticipated long-term outcome was the prevention of HPV-related
diseases, thereby decreasing morbidity and mortality.
Summary and Strength of the Evidence
Extensive research has addressed implementing the HPV vaccine in various
environments. Studies have demonstrated which methods were successful and where
improvements were needed. Data from these studies are summarized herein. Lander, Besson,
Rodrigues, Audureau, and Saba (2014) reported that implementing the HPV vaccine in lowincome countries using a no-cost method was highly effective. However, vaccination rates were
better when supply was uninterrupted; a consistent supply eliminated delays in administering the
vaccine (Ladner, Besson, Rodrigues, Audureau, & Saba, 2014). Thus, having the logistics in
place to ensure the student clinic had a consistent vaccine supply was important. Ladner et al.
(2014) also suggested that the best way to increase HPV vaccination rates was to establish a
school-based vaccination program where students could receive each of the three required doses
on campus (Ladner et al., 2014).
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Many factors contribute to a college student’s willingness to begin and complete the HPV
vaccine series. Marchand, Glenn, and Bastani (2012) found that among 178 community college
female students in Los Angeles, 43% demonstrated a three-dose completion rate, with students
who were studying a health-related major or were younger being more likely to start the vaccine
series. Another study examining the behaviors of Hispanic college women revealed that if a
student was obese and had not received the flu vaccine or scheduled a Pap smear in the past 12
months, she was less likely to receive the HPV vaccine (Cohen & Legg, 2014).
Alexander et al. (2014) investigated how best to encourage awareness and increase
vaccination rates among teen men. The authors suggested that awareness should focus on how
HPV is transmissible between partners. Emphasizing the negative consequences of not receiving
the vaccine was found to be more effective than stating the usual positive remarks about the
vaccine (Alexander et al., 2014). Lastly, Dominiak-Felden et al. (2013) stated that HPV
vaccination rates would increase if the message focused on the fact that the HPV vaccine
prevents genital warts and anal, oral, and penile cancers. Thus, messaging to develop awareness
should focus on the lack of life quality when a person is diagnosed with HPV-related lesions or
neoplasms (Dominiak-Felden et al., 2013).
Many researchers have concurred that completion of the three-dose series is low
compared to the already low initiation rate among the eligible population (Alexander et al.,
2014). When the HPV vaccine was encouraged along with screenings for other sexuallytransmitted diseases like HIV, the vaccination completion rate increased (McCave et al., 2013).
Electronic reminders via a healthcare portal or similar system, at an interval that does not
overwhelm patients, has also been shown to promote vaccination completion (Wright et al.,
2011).
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Between-group comparisons have revealed differences in HPV vaccination rates.
Disparities persist among minority populations and Caucasians in terms of receiving and being
aware of the HPV vaccination (Marchand et al., 2012; Osazuwa-Peters et al., 2017). The
Caucasian population was also more likely to receive and complete the HPV vaccination course
than their minority counterparts (Ratanasiripong et al., 2013). Regarding other demographics,
men are less likely to be vaccinated against HPV than women (McCave et al., 2013). Younger
eligible patients are more likely to receive the vaccine than those who are older, as the latter
group may believe it is too late to be vaccinated. Thus, promotional efforts should target
individuals who are older, low-income, minority, or male to increase vaccination rates among the
eligible population.
Methods
Project Intervention
Steps of the HPV vaccine implementation plan are outlined in Figure 1.

HPV vaccine
implementation plan
devloped in conjunction
with clinical manager,
project advisor, & mentor

Students informed of
availability of the HPV
vaccine via email

Figure 1. Implementation plan.

Clinic obtained and
stocked the HPV vaccine

Providers and staff were
educated on HPV vaccine
using materials provided
by Metropolitan Health
District and immunize.org

Staff used paper reminder
cards to schedule nurse
visit for the HPV vaccine

Paper checklist/computer
terminal cards were
implemented to alert
providers to recommend
vaccine to all eligible
students
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The vaccination process in the implementation plan was initiated either when an eligible
student requested or a provider offered the HPV vaccine to patients from 18 to 27 years old.
Although the eligible age criteria for receiving the HPV vaccine at the time of this study was 9 to
26 years old, 27-year-old students were considered candidates in the case at least one dose had
been received before age 26 and the series needed to be completed. Next, the provider and
student discussed the HPV vaccine to determine eligibility. If the student was eligible but
declined the vaccine despite provider-based education, the reason for refusal was documented in
the student’s electronic health record. If the student agreed to be vaccinated, he or she then
signed a consent form indicating an understanding of the risks and benefits of the HPV vaccine.
The student was also given a Vaccine Information Sheet. After the RN or LVN administered the
HPV vaccine, the front desk staff or MA scheduled the student for a nurse visit to receive the
next HPV vaccine dose; a wallet-size reminder card (see Figure 2) was provided to remind the
student about his or her next HPV vaccination nurse visit.

Figure 2. Wallet-size reminder.
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The HPV vaccine implementation plan was based on the Plan, Do, Check, and Act cycle.
A new component of the intervention was introduced every other week to increase the HPV
vaccination rate among university health professions students. Week 1 included staff education
on the HPV checklist (see Figure 3). Week 2 reinforced the previous week. Week 3 reminders
using the CDC advertising marketing campaign were posted on computer terminals in an area
visible to providers. Week 4 provided reinforcement of the posted reminders on clinic computer
terminals (see Figure 4). In Week 5, students in the clinic waiting room were offered an
immunize.org flyer as a handout; the flyer was also used as an email marketing tool, distributed
to all university health professions students, to encourage students to receive the vaccine. Weeks
6 through 8 focused on reinforcement of all intervention components.

Figure 3. HPV checklist.
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Figure 4. Computer terminal reminder.
During every week of the HPV vaccine implementation period, the DNP student
performed an audit of providers’ patient loads to identify students eligible for the vaccine. Each
provider was then assessed to determine the percentage of students offered and subsequently
given the HPV vaccine. If a provider had not completed the HPV checklists or initiated the
conversation with eligible students, then the graduate student spoke with the provider to
determine the reasons for not offering the HPV vaccine and discuss a plan for improvement.
Organizational Barriers and Facilitators
The primary barrier was that the HPV vaccine is not included in the requirements for
university attendance. Additionally, clinical rotations do not ask for it, providing no impetus for
the clinic to enforce the HPV vaccine. The university does not track the HPV vaccine in student
records or the student clinic, and assessments for the HPV vaccine are not routinely completed.
Moreover, men are almost never offered the vaccine although HPV occurs in men; this practice
does not correlate with the ACHA guidelines, which represent the benchmark to which
university student health clinics are held. The ACHA guidelines refer to the CDC guidelines as a
resource regarding which immunizations should be administered within the college setting. As
for organizational facilitators, the clinical manager and the Dean for Practice & Engagement
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supported the provision of the HPV vaccine. Stakeholders understood the importance of the
vaccine and wished to comply with the ACHA guidelines; thus, they were eager to promote HPV
vaccine implementation.
Ethical Considerations
An ethical issue identified in the literature was the belief that the vaccine would cause
individuals to be sexually active (CDC, 2016). Furthermore, vaccination does not prevent other
sexually transmitted infections, as the HPV vaccine does not protect against sexually transmitted
diseases; thus, additional protection through condom use should be encouraged. Staff and student
education are therefore imperative to dispelling biased and non-evidence-based beliefs.
Results
Objective 1: One hundred percent of providers and staff would be educated on the
importance of the HPV vaccine and the new vaccination program. [Goal met.]
All providers and staff completed the HPV PowerPoint education and the pre- and posttests (see Appendix A). Staff scores improved by 33% from pre- to post-test; however, barriers
were encountered. A Health Department representative was originally scheduled to present the
PowerPoint to the staff with, but many staff were occupied with patients and not enough were
available at the time of the presentation. Then, a PowerPoint voiceover link was provided as an
alternative to the live presentation, but no staff took advantage of this mode of presentation.
Lastly, a paper copy of the PowerPoint was provided to the staff. The staff still stated they were
too busy to complete the PowerPoint education and post-test; education completion was hence
delayed.
Objective 2: Provider recommendations for the HPV vaccine to eligible students would
increase from 0% initially to 50% post-implementation. [Goal not met.]
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Of 205 student visits during the implementation period, providers offered 10.7% of
students the vaccine (see Figure 5). All student visits were included; therefore, students who may
have completed the series prior to matriculating into the university were included in the total.

10.7%

89.3%

Figure 5. Percentage of provider HPV vaccine recommendations (N = 205).
Objective 3: The number of eligible students offered the HPV vaccine who received a
dose would increase from 0% initially to 50% post-intervention. [Goal met.]
Sixty-four percent of eligible students who were offered the HPV vaccine received the
immunization (see Figure 6). Students who had completed the HPV series prior to matriculating
were not included in the total because they were not considered eligible for the vaccine at the
time of their visit.

35.7%

64.3%

Figure 6. Percentage of eligible students receiving the HPV vaccine (n = 22).
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Objective 4: HPV vaccination rates among eligible students who visited the student
health clinic would increase from 0% initially to 60% post-intervention. [Goal not met.]
The overall clinic vaccination rate post-implementation was 4.5% (n = 197), assuming
that all 197 students not offered the HPV vaccine were eligible for it and had not completed the
HPV series prior to matriculating.
Discussion
Taking the above objectives as an outline for the HPV implementation project in the
student health clinic, each objective will be discussed in detail.
Objective 1
The main objective was to increase awareness of the HPV vaccine and the new HPV
vaccination program. A major component of the corresponding education was to emphasize that
both sexes can receive the vaccine as a preventative measure for genital warts as well as
oropharyngeal, anal, and cervical cancers. Ages for eligibility were also reviewed. The desired
outcome was to educate 100% of clinic providers and staff. This objective was measured by
comparing knowledge before the presentation to knowledge gained post-presentation
intervention by conducting a pre- and post-test. The pre- and post-test instrument was reliable
and valid according to city health department personnel.
The objective for this part of the HPV project was met, representing an important
milestone in the project. All providers and staff increased their knowledge of the HPV vaccine
and the new program. Therefore, the PowerPoint presentation was useful in providing staff
meaningful knowledge about the implementation of the HPV vaccine. Challenges in
implementing this part of the intervention included a lag time in completing the education
component, which delayed the project start. The scheduled date on which city health department
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personnel came to perform a presentation at the clinic was not a practical use of time, per the
clinical manager, and not all staff members could attend the meeting at the same time. The
scheduled presentation was canceled due to poor attendance. Time constraints in the clinic
rendered it difficult for staff to complete a 20-minute voiceover presentation. Staff also stated
they were too busy to complete the pre-test and post-test; thus, they were encouraged to increase
completion. Whole-staff completion of the education component of the HPV intervention project
was time-consuming.
Objective 2
Another main objective was to increase the rate at which clinic providers offered the
HPV vaccine to eligible students, increasing from a pre-intervention rate of 0% to 50% by
completion of the project. The method of measurement was to assess the number of total
appointments compared to information collected on the HPV checklists completed by providers
each week. This objective was not met due to many missed opportunities by providers to
recommend the HPV vaccine to eligible students. Providers stated they did not remember to
encourage eligible students to receive the vaccine. Other difficulties included a lack of pop-up
reminders in the electronic medical record system. Also, providers did not feel that
recommending the HPV vaccine was the main priority for patients who were being seen for a
different reason.
Some successes included the staff being able to follow the processes of providing
students with HPV-related education and having them sign the consent form. Once students
signed the consent form, then the RN or LVN administered the HPV vaccine. Finally, students
were given a reminder card to place in their wallet after the MA scheduled their next visit.
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Objective 3
The next objective was to increase the vaccination rate among eligible students who were
offered the vaccine from 0% to 50%. This objective was met. A success and strength of the HPV
vaccination project involved adult students’ ability to make an informed decision about whether
to receive the HPV vaccine based on recommendations and education from the provider.
Challenges included that some students did not know if they had received the HPV vaccination
previously or how many doses they had received. Many university students stated they would
need to check their immunization records to determine if they needed the HPV vaccine. Other
students were not interested in receiving the vaccine despite efforts to educate them on its
importance. Some students stated they were dose-complete.
Objective 4
The final objective was to increase the overall HPV vaccination rate among eligible
students by 60% post-intervention. In the interest of time, the focus was on the first-dose
initiation. This objective was measured by documenting how many people received at least one
dose of the HPV vaccine during the implementation period. This objective was not met.
Difficulties included providers not acknowledging the importance of offering the HPV vaccine.
They felt they did not have enough time to address each eligible student’s chief complaint and
recommend the HPV vaccine. In addition, despite an extensive HPV vaccination marketing
campaign, the effects of such advertising were minimal.
Limitations
An education-related limitation during the first part of the HPV project emerged when the
initial mode of presenting education to providers and staff was ineffective, resulting in varied
education attempts. First, a presentation with a health department representative was scheduled
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but was not attended. Many providers worked on different days, making it difficult to find a time
that accommodated their busy schedules. Thus, an audio accompaniment was offered to staff as
an independent alternative; however, staff reported issues accessing the audio PowerPoint, which
increased the lag time for education completion among providers and staff. The last option was a
printed PowerPoint for the staff to read. Providers and staff needed time to complete the pre-test,
education, and post-test. Many reminders from the DNP student and a staff luncheon were
offered before all providers and staff completed education and testing.
Additional limitations included providers not prioritizing offering the HPV vaccine to
eligible students. Although providers understood evidence-based research and that the vaccine
was part of the ACHA guidelines, they felt that the student’s chief complaint was the primary
purpose for the visit, and telling the student about the HPV vaccine took time away from the
presenting problem. Another problem was that the clinic continued to run out of stock of the
HPV vaccine during the implementation period. Lastly, students could not remember their HPV
vaccination status and thus had to decline the HPV vaccine when it was offered. Finally, the
reimbursement process when offering the HPV vaccine to university students needed to be
clarified. The clinic did not receive full reimbursement for the vaccine, likely due to entering the
wrong code when billing insurance companies.
Recommendations
Recommendations for the education component of the HPV vaccine implementation
program are to keep it simple for staff to complete. A paper copy of the PowerPoint would be an
ideal way to disseminate information among staff to be read at their convenience. More research
is needed regarding motivating staff to complete educational offerings; flexibility and patience
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appear to be key in this regard. Additionally, the CDC website and local public health
department should help providers remain abreast of the most up-to-date information.
Some suggestions to increase the rate of recommending the HPV vaccine to eligible
students include incorporating HPV vaccine eligibility and assessment into the electronic
medical record. This strategy will allow standardization of an assessment for required and
recommended student vaccinations. Another way to increase the vaccination rate among eligible
students includes encouragement by the clinical manager to enforce this policy among providers
in the student health clinic. Lastly, the addition of a reimbursement plan or a benefits coordinator
would facilitate higher HPV vaccination rates.
Implications for Practice
The providers at the university clinic are aware of the consequences of not following
evidence-based guidelines when it comes to the primary care of health professions students.
Enlightening providers and staff about this aspect of care could potentially decrease morbidity
and mortality among the university student population. An additional implication is financial;
this HPV project included insurance reimbursement and ensuring the clinic received funds for
administration of the HPV vaccine. Lastly, in terms of a provider-focused initiative, university
students may be more likely to consent to receive the HPV vaccine, if their primary care provider
recommends it.
For this project, the DNP-prepared nurse practitioner student applied evidence-based
scientific knowledge to the healthcare setting (Essential I). Inter-professional cooperation was
required for a collaborative project such as this; the DNP student worked with MAs, LVNs, RNs,
and providers (Essential VI). The project coordinator recognized gaps and missed opportunities
in the healthcare system and arranged a process improvement plan to address these deficits,
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reinforcing that DNPs are in a position to lead change for the better (Essential II). Using weekly
audits as a means of collecting and tracking data is reflective of the ways in which a DNPprepared nurse can harness healthcare information technology to improve healthcare (Essential
IV). The university student clinic had never had an HPV vaccination program; launching one
required policy development and modifications to clinical decision making and related processes
(Essential V). Overall, increasing the HPV vaccination rate is expected to lead to positive longterm outcomes, such as increasing students’ protection against HPV and its subsequent
morbidities.
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Appendix A
Education Pre- and Post-Test

HPV Education Test
Provider/Clinic Name:

TVFC

What is your current role or title with this practice? (Circle all that apply)

Primary TVFC Contact

Secondary TVFC Contact

Patient Care Staff (Physician, Nurse, PA, MA)

Clinic or Office Manager

Front Desk Staff/Administrative/Billing Staff

Please circle true or false for the questions below.
If you are unsure please circle “Not Sure”. Thus will help us better understand the areas that need

True

False

Not Sure:

HPV can affect anyone of any age?

True

False

Not Sure:

The HPV vaccince is not light sensitive and can be kept close to the
light?

True

False

Not Sure:

The HPV vaccine is only a 3 does series?

True

False

Not Sure:

The purpose of the HPV vaccine is to help prevent certain types of
cancer?

True

False

Not Sure:

Only girls need to receive the HPV vaccine?

True

False

Not Sure:

HPV cannot be passsed by skin-to-skin contact?

True

False

Not Sure:

The HPV vaccine is a live antigen?

